Home Cart Sign in  
Chemical Structure| 845959-50-4 Chemical Structure| 845959-50-4

Structure of Mitoquinone mesylate
CAS No.: 845959-50-4

Chemical Structure| 845959-50-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Mitoquinone mesylate is a TPP-based, mitochondrially targeted antioxidant designed to protect against oxidative damage.

Synonyms: MitoQ mesylate; MitoQ10 mesylate; Mitoquinone (mesylate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mitoquinone mesylate

CAS No. :845959-50-4
Formula : C38H47O7PS
M.W : 678.81
SMILES Code : O=C(C(CCCCCCCCCC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)=C4C)C(OC)=C(OC)C4=O.CS(=O)([O-])=O
Synonyms :
MitoQ mesylate; MitoQ10 mesylate; Mitoquinone (mesylate)
MDL No. :MFCD30747833

Safety of Mitoquinone mesylate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
3T3-L1 adipocytes 100 nM 30 min MitoQ attenuated malonic acid-induced Fgf21, UCP1 and Cidea gene upregulation, suggesting that malonic acid-induced upregulation of FGF21 signalling is partly dependent on malonate altering mitochondrial redox signalling. PMC11696296
A549 cells 1 μM 24 h To detect the effect of MitoQ on DEP-induced ROS levels, results showed that MitoQ did not significantly reduce ROS levels. PMC11251497
Normal rat kidney (NRK) cells 100 nM 48 h MitoQ scavenged mitochondrial superoxide and prevented the increased protein expression of PGC1α and CORE II following MnSOD knockdown. PMC3926114
hASCs 1 µM 48 h Mitoquinone was used to reduce mitochondrial reactive oxygen species (mtROS) and evaluate its effect on IDO activity. Results showed that Mitoquinone significantly reduced the response of P5 hASCs to IFN-γ stimulation, but had a lesser effect on P12 hASCs. PMC7988085
MLE12 cells 500 nM 30 min To evaluate the role of Mitoquinone in CdCl2-induced pyroptosis in MLE12 cells, the results showed that Mitoquinone significantly reduced CdCl2-induced mitochondrial ROS and the expression of pyroptosis-related proteins. PMC11590492
Normal rat kidney (NRK cells) 100 nM 48 h Mitoquinone prevented the increase in mitochondrial superoxide and nitrotyrosine following MnSOD knockdown by scavenging mitochondrial superoxide. PMC3926114
Platelets 5 μM 10 minutes To evaluate TRAP-6-induced platelet aggregation and P-selectin expression. Results showed that TRAP-6 (5 μM) significantly increased platelet aggregation (88% ± 4.74%), while MitoQ at 5 μM significantly reduced aggregation (58.3% ± 5.1%). TRAP-6-induced P-selectin expression was not affected by MitoQ. PMC7503844

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CdCl2-induced lung injury model Intraperitoneal injection 3 mg/kg Once daily for 7 days To evaluate CdCl2-induced lung injury and alveolar epithelial cell pyroptosis, the results showed that CdCl2 exposure significantly increased the lung tissue inflammation score and the expression of pyroptosis-related proteins. PMC11590492
Rats Cardiac metabolism model Oral 500 μM Daily for 2 weeks MitoQ treatment improved cardiac energetics during Na elevation, reduced lactate and alanine concentrations, and reversed the shift in redox balance. PMC11106256
Rats Maternal psychosocial stress model during pregnancy Intravenous injection 90 μg/kg Single injection, lasting 5 days To investigate the effects of MitoQ-NP on placental oxidative stress induced by maternal psychosocial stress and its impact on offspring behavior and neurobiology. Results showed that MitoQ-NP treatment reduced placental and maternal oxidative stress and prevented anxiety-like behavior and neurobiological changes in male offspring induced by prenatal stress. PMC7739187

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.47mL

0.29mL

0.15mL

7.37mL

1.47mL

0.74mL

14.73mL

2.95mL

1.47mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories